Sage Therapeutics Inc Expected To Post A Loss Of $1.51 A Share: Earnings Preview

Sage Therapeutics

07/02/2025 21:11

* SAGE Therapeutics Inc  SAGE.OQ   SAGE.O  is expected
to show a
fall in quarterly revenue when it reports  results on February
11 for the period ending December 31 2024
    * The Cambridge Massachusetts-based  company is expected to
report
a 81.5% decrease in revenue to $14.441 million from $77.97
million a year ago, according to the mean estimate from 17
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for SAGE Therapeutics Inc is
for a
loss of $1.51 per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 15
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for SAGE
Therapeutics
Inc is $8.83​, above​ its last closing price of $7.28. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2024  -1.53       -1.53      -1.53     Met     0.2
 Jun. 30 2024  -1.70       -1.66      -1.70     Missed  -2.5
 Mar. 31 2024  -1.64       -1.65      -1.80     Missed  -9.3​
 Dec. 31 2023  -1.65       -1.28      -1.80     Missed  -40.9
 ​​Sep.        -2.76       -2.73      -3.37     Missed  -23.4
 30 2023                                                
 Jun. 30 2023  -2.56       -2.55      -2.68     Missed  -4.9​
 Mar. 31 2023  -2.47       -2.50      -2.46     Beat    1.4
 Dec. 31 2022  -2.41       -2.39      -2.47     Missed  -3.5
 This summary was machine generated February 7 at 21:11 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)